Is it safe to stay on Wegovy long term?

The decision most people face after the first year

Many people notice real change within the first few months on Wegovy and then arrive at a point where they have to decide: is this something I continue, or is there a point at which it becomes riskier than it is useful? That is a genuinely reasonable question, not a sign of doubt about the medicine.

The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4mg for 68 weeks. Average weight loss was around 15% of body weight. Crucially, the trial also tracked what happened when participants stopped: weight returned, as did some of the cardiometabolic markers that had improved. That pattern is part of why prescribers talk about long-term treatment rather than a short course. You can read the NHS patient-level overview of semaglutide for a plain-English summary of the evidence base.

NICE, when recommending semaglutide under TA875, set a two-year limit specifically for NHS specialist services. That ceiling reflects commissioning decisions and resource constraints rather than a definitive safety cutoff. Private prescribers work from the same clinical evidence but assess each person's situation at every repeat review. The key factors: how much weight has been lost, whether any comorbidities have improved, how side effects have been tolerated, and whether continuing treatment still has a clear clinical rationale.

The side effects that matter most over time

Short-term GI effects (nausea, loose stools, some reflux) are familiar from the titration phase. For most people they ease. The more relevant question for long-term use is whether sustained exposure carries any risks that emerge only with time. Here the picture is still building, which is precisely why Wegovy carries the Black Triangle designation requiring the MHRA to gather additional post-marketing safety data.

The January 2026 MHRA Drug Safety Update on GLP-1 receptor agonists highlighted acute pancreatitis as an infrequent but serious risk. It is not a reason to avoid Wegovy, but it is a reason to take the warning symptom seriously: severe, persistent abdominal pain that spreads to the back, with or without vomiting, warrants urgent medical assessment rather than waiting it out. Our guide to Wegovy side effects covers this and the other effects to know about.

Gallbladder problems, including gallstones, are also associated with significant weight loss generally and have been reported with GLP-1 medicines. Sustained rapid weight change increases gallstone risk in any context. Your prescriber should know if you develop upper-right abdominal pain, especially after eating. Other effects to monitor over time include any changes in kidney function if you have experienced significant vomiting or diarrhoea, and (separately from physical symptoms) any changes in mood. Less talked-about side effects of Wegovy include some that patients are surprised to encounter.

When to get medical help, and how to report concerns

Some symptoms need prompt attention rather than a call booked for next week. Seek urgent medical help for: severe or persistent stomach pain radiating to the back; signs of an allergic reaction such as facial swelling, hives or difficulty breathing; symptoms of dehydration after prolonged vomiting or diarrhoea; or any new, significant changes in vision. Do not wait for a scheduled review if something feels wrong.

If you suspect a side effect you have not been warned about, or one that feels more severe than expected, you can report it directly to the MHRA through the Yellow Card reporting scheme, patients can submit reports themselves, not just healthcare professionals. This scheme is how post-marketing safety data gets collected and why it matters. It is one of the main mechanisms protecting everyone on these medicines long term.

Keeping your prescriber updated between formal reviews is good practice, not fussiness. A question that comes in on a Tuesday afternoon is exactly what aftercare support is for. If you have specific concerns about long-term safety that have not been addressed, our support team can direct you to the right clinical contact.

How long-term safety is monitored at a clinical level

Staying on Wegovy safely is not just about the medicine itself, it is about the clinical infrastructure around it. At every repeat, a prescriber should be reviewing whether treatment is still appropriate. That means checking weight trajectory, any new medical history, any change in other medicines you take (some interactions affect absorption or safety), and whether the benefit is still outweighing any burden from side effects. No repeat should be automatic.

At nume, every order is clinically re-reviewed before dispatch, there is no subscription model that sends a new pen without a prescriber looking at your records again. You can read about the longer-term safety picture for semaglutide more broadly, and our guidance on how long it is safe to take Wegovy covers the decision framework in more detail. For the wider question of how safe Wegovy is long term, our prescribers discuss both the evidence and your individual circumstances as part of every review. If you are thinking about starting or continuing treatment, you can speak to our prescribers through the free consultation, suitability and side effects are always part of that conversation.